# Vutrisiran: HELIOS-B Study

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for AMVUTTRA<sup>®</sup> (vutrisiran) is provided <u>here</u>. Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at <u>RNAiScience.com</u>.

### SUMMARY

- HELIOS-B was a phase 3, global, randomized, double-blind, placebo-controlled multicenter study designed to evaluate the efficacy and safety of vutrisiran in patients with ATTR-CM including both hATTR and wtATTR.<sup>1</sup>
- The study met the primary endpoint and vutrisiran reduced the risk of all-cause mortality and recurrent CV events compared with placebo during the double-blind period (up to 36 months). The HR was 0.72 (95% CI 0.56, 0.93; P=0.01) in the overall population and 0.67 (95% CI 0.49, 0.93; P=0.02) in the monotherapy population.<sup>1</sup>
- The study met all secondary endpoints with vutrisiran demonstrating statistically significant differences compared with placebo in all-cause mortality through 42 months and 6-MWT, KCCQ-OS, and NYHA class at 30 months.<sup>1</sup>
- In the overall population, the mean trough percent reduction in serum TTR level was 81.0% (95% CI 79.0, 83.0) at month 30.<sup>1</sup>
- There were improvements in exploratory endpoints with vutrisiran compared with placebo for NTproBNP, troponin I, peak longitudinal strain, and EuroQoL-5D-5L at 30 months.<sup>1</sup>
- The majority of AEs in the trial were mild or moderate and similar between treatment arms.<sup>2</sup>

# **INDEX**

<u>Study Design</u> – <u>Baseline Characteristics and Patient Demographics</u> – <u>Efficacy Results</u> – <u>Safety</u> – <u>Abbreviations</u> – <u>References</u>

# **STUDY DESIGN**

HELIOS-B was a phase 3, global, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of vutrisiran in patients with ATTR-CM, including both hATTR and wtATTR. Patients were randomized (1:1) to receive either vutrisiran 25 mg (n=326) or placebo (n=329) every 3 months by subcutaneous injection for up to 36 months. The primary endpoint was the composite endpoint of all-cause mortality and recurrent CV events (CV hospitalizations and urgent heart failure visits) at the end of the double-blind exposure period in the overall population and in the vutrisiran monotherapy population (patients not receiving tafamidis at baseline). After the double-blind treatment period, all eligible patients remaining on the study were allowed to receive vutrisiran in an ongoing OLE.<sup>1</sup>

# **Primary Endpoint**

The primary endpoint was the composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) at Month 33 or 36, which was analyzed using a modified Andersen-Gill model with a robust variance estimator (LWYY model). The primary endpoint was analyzed in both the overall study population and the vutrisiran monotherapy population (patients who were not on tafamidis at baseline). These endpoints were tested in parallel. Heart transplantation or implantation of a left ventricular assist device, or both, were treated as deaths from any cause. Sensitivity analysis was performed using a Mantel-Haenszel-type stratified win ratio method, stratified by baseline NT-proBNP. Predefined subgroups were stratified according to tafamidis use at baseline, ATTR disease type (wtATTR versus hATTR), NYHA class, and age at baseline.<sup>1,3</sup>

# Secondary Endpoints

The secondary endpoints were related to functional capacity, patient-reported health status and healthrelated quality of life, as well as additional assessments of mortality and severity of clinical HF symptoms, including:<sup>1</sup>

- All-cause mortality, including up to 6 months of OLE data (up to Month 42)
- Change from baseline in 6-MWT at Month 30
- Change from baseline in the KCCQ-OS at Month 30
- Change from baseline in NYHA class at Month 30

# **Exploratory Endpoints**

Exploratory endpoints included NT-proBNP level, troponin I level, peak longitudinal strain, and quality of life assessed with the EuroQol 5-Dimension 5-Level questionnaire. Serum TTR levels were measured as a pharmacodynamic endpoint. Safety was monitored throughout the trial and included assessments of adverse events, clinical laboratory measures, and vital signs.<sup>1</sup>

### **Inclusion and Exclusion Criteria**

Select inclusion and exclusion criteria for HELIOS-B are presented in Table 1.<sup>1</sup>

# Table 1. HELIOS-B Key Inclusion and Exclusion Criteria.<sup>1</sup>

Inclusion Criteria	Exclusion Criteria
Age 18-85 years	NYHA Class IV heart failure
• Documented diagnosis of ATTR-CM (either	• NYHA Class III with NAC ATTR Stage 3
hATTR or wtATTR)	• PND Score IIIa, IIIb, or IV
• Medical history of HF with at least 1 prior	• eGFR <30 mL/min/1.73 m <sup>2</sup>
hospitalization for HF or clinical evidence of HF	• Cardiomyopathy not associated with ATTR
• Patient meets one of the following criteria:	
<ul> <li>Tafamidis-naïve and not actively planning to</li> </ul>	
commence treatment with tafamidis during the	
first 12 months following randomization; or	
• On tafamidis (Note: must be on-label use of	
commercial tafamidis per the approved indication	
and dose in the country of use)	
• NT-proBNP >300 pg/mL and <8500 pg/mL (or	
>600 pg/mL and <8500 pg/mL for patients with	
atrial fibrillation)	
• Ability to complete $\geq 150$ m on the 6-MWT	

Abbreviations: 6-MWT = 6-minute walk test; ATTR = transthyretin amyloidosis; ATTR-CM = transthyretin amyloidosis with cardiomyopathy; CV = cardiovascular; eGFR = estimated glomerular filtration rate; hATTR = hereditary transthyretin amyloidosis; HF = heart failure; NAC = National Amyloidosis Centre; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association; PND = polyneuropathy disability; wtATTR = wild-type transthyretin amyloidosis.

### **BASELINE DEMOGRAPHICS & PATIENT CHARACTERISTICS**

There were 326 patients randomly assigned to the vutrisiran group and 329 patients to the placebo group in the overall population. Of the patients from the overall population, 60% (196 of 326 patients) in the vutrisiran group and 60% (199 of 329 patients) in the placebo group were not taking tafamadis at baseline (monotherapy population). Patient baseline characteristics were comparable between the groups, except for higher NT-proBNP and troponin I values in the vutrisiran group than the placebo group in the monotherapy population as shown in **Table 2**. Baseline demographics and clinical characteristics were not substantially different between the monotherapy population and overall population. Forty-four of 196 (22%) of patients in the vutrisiran group and 41 of 199 (21%) of patients in the placebo group started tafamidis after randomization in the monotherapy population.<sup>1</sup>

	Overall P	opulation	Monotherapy Population		
<b>Baseline Characteristics</b>	Vutrisiran (n=326)	Placebo (n=328) <sup>a</sup>	Vutrisiran (n=196)	Placebo (n=199)	
Age at randomization,	77.0 (45-85)	76.0 (46-85)	77.5 (46-85)	76.0 (53-85)	
years, median (range)	77.0 (43-65)	70.0 (40-05)	77.5 (40-05)	70.0 (55-05)	
Male sex, n (%)	299 (92)	306 (93)	178 (91)	183 (92)	
Race, $n (\%)^b$			1,0()1)	100 ()=)	
White	277 (85)	275 (84)	169 (86)	169 (85)	
Asian	18 (6)	19 (6)	12 (6)	15 (8)	
Black/African American	23 (7)	24 (7)	10 (5)	11 (6)	
Other/Not reported	8 (2)	10 (3)	5 (3)	4 (2)	
wtATTR, no. (%)	289 (89)	289 (88)	173 (88)	174 (87)	
Time since diagnosis of ATTR, years, median (range)	0.86 (0-11.1)	1.03 (0-10.8)	0.50 (0-8.3)	0.63 (0-6.2)	
Tafamidis use at baseline, no. (%)	130 (40)	129 (39)	-	-	
Time on tafamidis prior to trial start, months, median (range)	9.2 (1.1-65.3)	11.3 (1.1-65.5)	-	-	
NYHA Class, n (%)					
Ι	49 (15)	35 (11)	15 (8)	12 (6)	
II	250 (77)	258 (79)	172 (88)	169 (85)	
III	27 (8)	35 (11)	9 (5)	18 (9)	
NAC <sup>c</sup> ATTR stage, n (%)					
1	208 (64)	229 (70)	113 (58)	138 (69)	
2	100 (31)	87 (27)	68 (35)	55 (28)	
3	18 (6)	12 (4)	15 (8)	6 (3)	
Laboratory parameters, median (IQR)					
NT-proBNP, pg/mL	2021 (1138- 3312)	1801 (1042- 3082)	2402 (1322- 3868)	1865 (1067-3099)	
High-sensitivity troponin I level, pg/mL	71.9 (44.9-115.9)	65.2 (41.1-105.5)	76.3 (48.4-138.8)	62.2 (39.2-105.6)	

Table 2. Baseline Patient Demographics and Clinical Characteristic	Table 2	2. Baseline	Patient	Demographi	ics and <b>(</b>	Clinical	Characteristics.	1
--	---------	-------------	---------	------------	------------------	----------	------------------	---

Abbreviations: ATTR = transthyretin amyloidosis; IQR = interquartile range; NAC = National Amyloidosis Centre; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association; wtATTR = wild-type transthyretin amyloidosis<sup>a</sup>One patient withdrew and did not receive study drug.<sup>3</sup>

<sup>b</sup>Race was reported by the patients.

"NAC stages are determined on the basis of the levels of the serum biomarkers NT-proBNP and estimated glomerular filtration rate.

#### **EFFICACY RESULTS**

#### Primary Endpoint: All-Cause Mortality and Recurrent CV Events


Treatment with vutrisiran reduced the risk of all-cause mortality and recurrent CV events; HR 0.72 (95% CI 0.56, 0.93; P=0.01) in the overall population and HR 0.67 (95% CI 0.49, 0.93; P=0.02) in the monotherapy population. Prespecified win ratio sensitivity analyses in both populations were consistent with the results of the primary analysis. The time to first CV event or all-cause mortality in the overall population and monotherapy population are shown in **Figures 1 and 2, and Table 3**, respectively.<sup>1</sup>


	Overall Population			Monotherapy Population		
End Point	Vutrisiran (n=326)	Placebo (n=328)	Measure of Effect	Vutrisiran (n=196)	Placebo (n=199)	Measure of Effect
Death from any cause and recurrent CV events – HR (95% CI), P-value			0.72 (0.56 to 0.93), P=0.01			0.67 (0.49 to 0.93), P=0.02
Death from any cause – HR (95% CI), P-value			0.69 (0.49 to 0.98), P=0.04			0.71 (0.47 to 1.06), P=0.12
Recurrent CV events – relative rate ratio (95% CI), P-value			0.73 (0.61 to 0.88), P=0.001			0.68 (0.53 to 0.86), P=0.001
Patients with at least one event – no. (%)	125 (38)	159 (48)		76 (39)	105 (53)	
Death from any cause <sup>a</sup> Recurrent CV events	51 (16) 112 (34)	69 (21) 133 (41)		36 (18) 66 (34)	46 (23) 87 (44)	

Table 3. Primary End Point and Patients With At Least One Event. <sup>1</sup>	Table 3. Pr	imary End	Point and I	Patients Wi	th At Least	<b>One Event</b> . <sup>1</sup>
---	-------------	-----------	-------------	-------------	-------------	---------------------------------

Abbreviations: CI = confidence interval; CV = cardiovascular; HR = hazard ratio


<sup>a</sup>Three patients in the vutrisiran group and four in the placebo group had a heart transplantation. No patients had implantation of a left ventricular assist device.





Abbreviations: CV = cardiovascular; CI = confidence interval.

Figure 2. Time to All-Cause Mortality or CV Event in the Monotherapy Population.<sup>1</sup>



Vutrisiran	196 (0)	172 (22)	157 (34)	141 (49)	131 (57)	119 (69)	32 (76) 0 (76)
Placebo	199 (0)	175 (22)	152 (43)	130 (60)	116 (72)	95 (93)	26 (105) 0 (105)

Abbreviations: CV = cardiovascular; CI = confidence interval.

Similar effects were observed in all-cause mortality and recurrent CV events across all prespecified subgroups shown in Figure 3 and Figure 4.<sup>1</sup>

Figure 3. Al	I-Cause Mortality and	<b>CV</b> Events in Prespecified Subgroups in the Overall Population. <sup>1</sup>
Subgroup	No. of Patients	Hazard Ratio (95% CI)

Beech			(
Overall	654		0.72 (0.56-0.93)
Age			
<75 yr	257	<b>⊢−−−</b> +	0.55 (0.35-0.85)
≥75 yr	397	F	0.81 (0.58-1.11)
Tafamidis use at ba	seline		
No	395	·── <b>─</b> ──1	0.67 (0.49-0.93)
Yes	259	<b>⊢</b> +	0.79 (0.51-1.21)
ATTR disease type			
Variant	76	· · · · · · · · · · · · · · · · · · ·	0.92 (0.49-1.72)
Wild type	578	<b>⊢</b> ∎−−1	0.67 (0.51-0.90)
NYHA class			
l or ll	592	<b>⊢</b>	0.73 (0.55-0.96)
III	62	• • · · · · · · · · · · · · · · · · · ·	0.68 (0.33-1.41)
Baseline NT-proBN	P level		
≤2000 pg/ml	342	<b>⊢</b>	0.53 (0.35-0.79)
>2000 pg/ml	312	F	0.80 (0.56-1.13)
	0.25	0.50 1.00 2.00	

Vutrisiran Better Placebo Better

Abbreviations: ATTR = transthyretin amyloidosis; CI = confidence interval; CV = cardiovascular; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association

i opulation.			
Subgroup	No. of Patients	Hazard Rat	io (95% CI)
Overall	395	<b>⊢_</b> ∎	0.67 (0.49–0.93)
Age			
<75 yr	153	·	0.53 (0.32-0.88)
≥75 yr	242	· • • •	0.72 (0.47-1.10)
ATTR disease type			
Variant	48	F	- 0.67 (0.31-1.44)
Wild type	347	F	0.66 (0.45-0.95)
NYHA class			
l or ll	368	· • •	0.73 (0.53-1.02)
III	27		0.31 (0.09-1.02)
Baseline NT-proBNP lev	vel		
≤2000 pg/ml	188	· · · · · · · · · · · · · · · · · · ·	0.50 (0.28-0.92)
>2000 pg/ml	207	· • •	0.71 (0.47-1.07)
	0.125	0.250 0.500 1.000	2.000
		Vutrisiran Better Pla	acebo Better

Figure 4. All-Cause Mortality and CV Events in Prespecified Subgroups in the Monotherapy Population.<sup>1</sup>

Abbreviations: ATTR = transthyretin amyloidosis; CI = confidence interval; CV = cardiovascular; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association

#### **Secondary Endpoints**

#### All-Cause Mortality


Vutrisiran reduced all-cause mortality as shown in **Table 4** through up to 42 months of follow-up vs. placebo in the overall population (HR 0.65 [95% CI 0.46, 0.90], P=0.01; **Figure 5**), and monotherapy population (HR 0.66 [95% CI 0.44, 0.97], P=0.045; **Figure 6**).<sup>1</sup>

#### Table 4. Secondary End Point and Patients Who Died.<sup>1</sup>

	<b>Overall Population</b>			Monotherapy Population			
End Point	Vutrisiran (n=326)	Placebo (n=328)	Measure of Effect	Vutrisiran (n=196)	Placebo (n=199)	Measure of Effect	
Death from any cause through 42 months – HR (95% CI), P-value			0.65 (0.46 to 0.9), P=0.01			0.66 (0.44 to 0.97), P=0.045	
Patients who died – no. (%)	60 (18)	85 (26)		43 (22)	58 (29)		


Abbreviations: CI = confidence interval; HR = hazard ratio.






Placebo 328 (0) 321 (7) 314 (14) 299 (29) 290 (38) 271 (57) 180 (74) 24 (85) 0 (85)

Abbreviations: CI = confidence interval





Abbreviations: CI = confidence interval

In both populations, similar effects were observed in all-cause mortality across all prespecified subgroups shown in **Figure 7** and **Figure 8**. Sensitivity analyses of the secondary endpoint were consistent with the secondary endpoint analysis.<sup>1</sup>

Subgroup	NO. OF Patier		
Overall	654	F	0.65 (0.46-0.90)
Age			
<75 yr	257	F	0.55 (0.29-1.04)
≥75 yr	397	F	0.69 (0.46-1.01)
Tafamidis use at baselin	e		
No	395	F	0.66 (0.44-0.97)
Yes	259	F = = = +1	0.59 (0.32-1.08)
ATTR disease type			
Variant	76	F	0.89 (0.39-2.03)
Wild type	578	F	0.61 (0.42-0.88)
NYHA class			
l or II	592	F	0.66 (0.47-0.94)
111	62	F	0.58 (0.20-1.69)
Baseline NT-proBNP lev	el		
≤2000 pg/ml	342	<b>⊢</b> •	0.35 (0.18-0.66)
>2000 pg/ml	312	F - 8 - 1	0.83 (0.55-1.24)
	-	0.25 0.50 1.00 2.00	
	-		►

#### Figure 7. All-Cause Mortality in Prespecified Subgroups in the Overall Population.<sup>1</sup> Subgroup No. of Patients Hazard Ratio (95% CI)

 Vutrisiran Better
 Placebo Better

 Abbreviations: ATTR = transthyretin amyloidosis; CI = confidence interval; CV = cardiovascular; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association

Figure 8. All-	Cause N	/lortality i	n Prespecified Subgroups in the Mo	notherapy Population. <sup>1</sup>
		C =		

Subgroup	No. of Patients	s Hazard Ratio (95% CI)		
Overall	395		••••	0.66 (0.44-0.97)
Age				, , , , , , , , , , , , , , , , , , , ,
<75 yr	153	H		0.58 (0.28-1.20)
≥75 yr	242			0.68 (0.42-1.09)
ATTR disease type				
Variant	48	H	-	0.67 (0.25-1.78)
Wild type	347	<b>—</b>		0.65 (0.42-1.00)
NYHA class				
l or ll	368	⊢		0.70 (0.47-1.06)
III	27 🔫	-		0.19 (0.02-1.63)
Baseline NT-proBNF	level			
≤2000 pg/ml	188	<b>⊢</b>		0.43 (0.18-1.01)
>2000 pg/ml	207	⊢		0.75 (0.48-1.18)
	0.125	0.250 0.50	0 1.00	2.00
		Vutrisiran Better	Plac	ebo Better

Abbreviations: ATTR = transthyretin amyloidosis; CI = confidence interval; CV = cardiovascular; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association

#### **Other Secondary Endpoints**

**Table 5** provides results from other secondary endpoints related to functional capacity, patient-reported health-status and patient-reported health quality of life, and severity of heart failure symptoms.<sup>1</sup>

### **Table 5. Other Secondary Endpoints.**<sup>1</sup>

	Overall Population		Monotherapy Population	
	Vutrisiran	Placebo	Vutrisiran	Placebo
End Point	(n=326)	(n=328)	(n=196)	(n=199)
6-MWT change from baseline at				
30 months, meters				
LS mean (95% CI)	-45.4 (-54.5,	-71.9 (-81.3,	-59.7 (-72.7,	-91.8 (-104.4,
	-36.3)	-62.4)	-46.7)	-79.2)
LS mean difference (95% CI),	26.5 (13.4, 39.6), P<0.001		32.1 (14.0, 50.2), P<0.001	
P value				
KCCQ-OS change from baseline				
at 30 months, points				
LS mean (95% CI)	-9.7 (-12.0,	-15.5 (-18.0,	-10.8 (-14.1,	-19.5 (-22.9,
	-7.4)	-13.0)	-7.5)	-16.1)
LS mean difference (95% CI),	5.8 (2.4, 9.2), P<0.001		8.7 (4.0, 13.4), P<0.001	
P value				
NYHA Class change from				
baseline at 30 months				
Stable or improved, %	68	61	66	56
Adjusted difference in % of	8.7 (1.3, 16.1), P=0.02		12.5 (2.7, 22.2), P=0.01	
patients with stable or				
improved (95% CI), P value				

Abbreviations: 6-MWT = 6-minute walk test; CI = confidence interval; KCCQ-OS = Kansas City Cardiomyopathy Questionnaire-Overall Summary; LS = least squares; NYHA = New York Heart Association


 Table 6 provides results for select exploratory endpoints.

#### Table 6. Exploratory Endpoints.<sup>3</sup>

	Overall Population		Monotherapy Population	
End Point	Vutrisiran (n=326)	Placebo (n=328)	Vutrisiran (n=196)	Placebo (n=199)
NT-proBNP fold-change from baseline at 30 months				` / /
Geometric mean (95% CI)	1.19 (1.11, 1.28)	1.75 (1.62, 1.89)	1.30 (1.17, 1.45)	2.28 (2.04, 2.55)
Geometric fold-change ratio (95% CI)	0.68 (0.61, 0.76)		0.57 (0.49, 0.66)	
Troponin I fold-change from baseline at 30 months				
Geometric mean (95% CI)	0.94 (0.88, 1.00)	1.37 (1.28, 1.47)	1.01 (0.92, 1.12)	1.85 (1.68, 2.03)
Geometric fold-change ratio (95% CI)	0.68 (0.62, 0.75)		0.55 (0.48, 0.63)	
Peak longitudinal strain change from baseline at 30 months, %				
LS mean (SEM)	0.95 (0.17)	2.18 (0.19)	1.07 (0.26)	2.37 (0.26)
LS mean difference (95% CI)	-1.23 (-1.73, -0.73)		-1.30 (-2.01, -0.59)	
EuroQoL-5D-5L Index change from baseline at 30 months				
LS mean (SEM)	-0.03 (0.008)	-0.06 (0.008)	-0.03 (0.011)	-0.08 (0.011)
LS mean difference (95% CI) Abbreviations: CI = confidence interval: LS = le	0.03 (0.01, 0.05)		0.05 (0.02, 0.08)	

Abbreviations: CI = confidence interval; LS = least squares; EuroQoL-5D-5L = EuroQoL 5-dimensions-5 levels; NT-proBNP = N-terminal pro-brain natriuretic peptide; SEM = standard error of the mean

In the overall population, the mean trough percent reduction in serum TTR level was 81.0% (95% CI 79.0, 83.0) at month 30 as shown in **Figure 9**.<sup>1</sup>





#### SAFETY

In the overall population, the proportion of patients with at least one AE was similar between treatment arms, and the majority of AEs were mild or moderate. Cardiac AEs occurred at similar or lower rates with vutrisiran than placebo.<sup>2</sup> A summary of the safety results during the double-blind period are presented in **Table 7.**<sup>3</sup> There were no clinically relevant changes in laboratory measures (including hematologic measures, blood chemistry measures, liver function tests, and renal function tests), vital signs, or electrocardiograms in either treatment arm.<sup>1</sup>

Event $n(0/)$	Overall Population			
Event, n (%)	Vutrisiran (N=326)	Placebo (N=328)		
At least 1 AE	322 (99)	323 (98)		
Any SAE <sup>a</sup>	201 (62)	220 (67)		
Any severe AE <sup>b</sup>	158 (48)	194 (59)		
Cardiac AEs	227 (70)	242 (74)		
Cardiac SAEs	116 (36)	124 (38)		
Any AE leading to treatment discontinuation	10 (3)	13 (4)		
Any AE leading to death <sup>c</sup>	49 (15)	63 (19)		

Table 7. Safety Summary.<sup>3</sup>

Abbreviations: AE = adverse event; SAE = serious adverse event.

<sup>a</sup>Serious AEs were defined as AEs that resulted in death, were life-threatening, resulted in inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or clinically significant disability or incapacity, were a congenital anomaly or birth defect, or were important medical events as determined by the investigators.

<sup>b</sup>Severe AEs were defined as AEs for which more than minimal, local, or noninvasive intervention was received; which had a severe effect on limiting self-care activities of daily living; or which had the potential for life-threatening consequences or death.

<sup>c</sup>Deaths that occurred after the end of study visit or after the data cut-off date were not included.

#### **ABBREVIATIONS**

6-MWT = 6-minute walk test; AE = adverse event; ATTR-CM = transthyretin amyloidosis with cardiomyopathy; CI = confidence interval; CV = cardiovascular; eGFR = estimated glomerular filtration rate; EuroQoL-5D-5L = EuroQoL 5-dimensions-5 levels; hATTR = hereditary transthyretin amyloidosis; HF = heart failure; HR = hazard ratio; IQR = interquartile range; KCCQ = Kansas City Cardiomyopathy Questionnaire-Overall Summary; LWYY = Lin-Wei-Yang-Ying; NAC = National Amyloidosis Centre;

NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA = New York Heart Association; OLE = open-label extension; PND = polyneuropathy disability; TTR = transthyretin; wtATTR= wild-type transthyretin amyloidosis.

Updated 4 Sept 2024

#### REFERENCES

- 1. Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med.* August 2024. doi:10.1056/NEJMoa2409134
- 2. Fontana M, Berk JL, Gillmore JD, et al. Primary results from HELIOS-B, a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. Presented at: European Society of Cardiology (ESC) Congress; August 30-September 2, 2024; London, UK.
- 3. Supplement to: Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. *N Engl J Med.* 2024. doi:10.1056/NEJMoa2409134